Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARVEL2: methylprednisolone adjunct to endovascular thrombectomy for large vessel occlusion stroke
ChiCTR2500098085Phase 4Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylprednisolone in ischemic stroke and Large-Vessel Ischemic Stroke (LVO) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Change in 90-day modified Rankin Scale score. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
methylprednisolone
03
Conditions
ischemic strokeLarge-Vessel Ischemic Stroke (LVO)
Beyond the preview
Go deeper on ChiCTR2500098085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098085.